New monoclonal antibodies for the treatment of acute lymphoblastic leukemia

Leukemia Research

Volumn 49, Issue , 2016, Pages 13-21

  Farhadfar, Nosha ^a   Litzow, Mark R ^a  

^a MAYO CLINIC   (United States)

Author keywords

Acute lymphoblastic leukemia (ALL); Monoclonal antibodies; Targeted therapy

Indexed keywords

BLINATUMOMAB; COLTUXIMAB RAVTANSINE; DENINTUZUMAB MAFODOTIN; EPRATUZUMAB; INOTUZUMAB OZOGAMICIN; MONOCLONAL ANTIBODY; MOXETUMOMAB PASUDOTOX; OBINUTUZUMAB; OFATUMUMAB; RITUXIMAB; ANTINEOPLASTIC AGENT; B LYMPHOCYTE ANTIGEN;

ACUTE LYMPHOBLASTIC LEUKEMIA; CANCER CHEMOTHERAPY; CANCER SURVIVAL; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; HUMAN; NONHUMAN; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; REVIEW; TREATMENT DURATION; IMMUNOLOGY; MOLECULARLY TARGETED THERAPY; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROCEDURES;

ANTIBODIES, MONOCLONAL; ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE; ANTINEOPLASTIC AGENTS; HUMANS; MOLECULAR TARGETED THERAPY; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

EID: 84981156388     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2016.07.009     Document Type: Review

References (72)

1. [1] http://seer.cancer.gov/statfacts, SEER Stat Fact Sheets: Acute Lymphocytic Leukemia (ALL) (2015).
2. [2] Pulte, D., Gondos, A., Brenner, H., Improvement in survival in younger patients with acute lymphoblastic leukemia from the 1980 to the early 21 st century. Blood 113:7 (2009), 1408–1411.
3. [3] Pui, C.H., et al. Childhood acute lymphoblastic leukemia: progress through collaboration. J. Clin. Oncol. 33:27 (2015), 2938–2948.
4. [4] Boissel, N., et al. Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. J. Clin. Oncol. 21:5 (2003), 774–780.
5. [5] Huguet, F., et al. Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study. J. Clin. Oncol. 27:6 (2009), 911–918.
6. [6] Oriol, A., et al. Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group. Haematologica 95:4 (2010), 589–596.
7. [7] Gokbuget, N., et al. Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. Blood 120:10 (2012), 2032–2041.
8. [8] Tavernier, E., et al. Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial. Leukemia 21:9 (2007), 1907–1914.
9. [9] Nadler, L.M., et al. A unique cell surface antigen identifying lymphoid malignancies of B cell origin. J. Clin. Invest. 67:1 (1981), 134–140.
10. [10] Czuczman, M.S., et al. Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels. Clin. Cancer Res. 14:5 (2008), 1561–1570.
11. [11] Raponi, S., et al. Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases. Leuk. Lymphoma 52:6 (2011), 1098–1107.
12. [12] Piccaluga, P.P., et al. Surface antigens analysis reveals significant expression of candidate targets for immunotherapy in adult acute lymphoid leukemia. Leuk. Lymphoma 52:2 (2011), 325–327.
13. [13] Borowitz, M.J., et al. Prognostic significance of fluorescence intensity of surface marker expression in childhood B-precursor acute lymphoblastic leukemia. A pediatric oncology group study. Blood 89:11 (1997), 3960–3966.
14. [14] Jeha, S., et al. Prognostic significance of CD20 expression in childhood B-cell precursor acute lymphoblastic leukemia. Blood 108:10 (2006), 3302–3304.
15. [15] Thomas, D.A., et al. Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia. Blood 113:25 (2009), 6330–6337.
16. [16] Chang, H., Jiang, A., Brandwein, J., Prognostic relevance of CD20 in adult B-cell precursor acute lymphoblastic leukemia. Haematologica 95:6 (2010), 1040–1042 author reply 1042.
17. [17] McLaughlin, P., et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J. Clin. Oncol. 16:8 (1998), 2825–2833.
18. [18] McLaughlin, P., Hagemeister, F.B., Grillo-Lopez, A.J., Rituximab in indolent lymphoma: the single-agent pivotal trial. Semin. Oncol. 26:5 Suppl. 14 (1999), 79–87.
19. [19] Coiffier, B., et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N. Engl. J. Med. 346:4 (2002), 235–242.
20. [20] Romaguera, J.E., et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J. Clin. Oncol. 23:28 (2005), 7013–7023.
21. [21] Keating, M.J., et al. Early results of a chemoimmunotherapy regimen of fludarabine: cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J. Clin. Oncol. 23:18 (2005), 4079–4088.
22. [22] Tam, C.S., et al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 112:4 (2008), 975–980.
23. [23] Thomas, D.A., et al. Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. J. Clin. Oncol. 28:24 (2010), 3880–3889.
24. [24] Hoelzer, D., Huettmann, A., Kaul, F., et al. Immunochemotherapy with rituximab improves molecular CR rate and outcome In CD20+ B-lineage standard and high risk patients; Results of 263 CD20+ patients studied prospectively In GMALL study 07/2003 [abstract]. ASH Annual Meeting, 116, 2010, 170.
25. [25] Maury, S., Chevret, S., Thomas, X., et al. Addition of rituximab improves the outcome of adult patients with CD20-positive, Ph-negative, B-cell precursor acute lymphoblastic leukemia (BCP-ALL): results of the randomized Graall-R 2005 study [Abstract]. American Society of Hematology Meeting, Plenary Scientific Session, 2015.
26. [26] Cheson, B.D., Ofatumumab, a novel anti-CD20 monoclonal antibody for the treatment of B-cell malignancies. J. Clin. Oncol. 28:21 (2010), 3525–3530.
27. [27] Jabbour, E., Kantarjian, H., Phase II study of the hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with CD-20 positive ALL. ASCO Annual Meeting, 2014 Abstract 7065.
28. [28] Teeling, J.L., et al. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J. Immunol. 177:1 (2006), 362–371.
29. [29] Hillmen, P., et al. Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial. Lancet 385:9980 (2015), 1873–1883.
30. [30] Wierda, W.G., et al. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J. Clin. Oncol. 28:10 (2010), 1749–1755.
31. [31] Hagop, K., et al. Phase II study of the hyper-CVAD regimen In combination with ofatumumab as frontline therapy for adults with CD-20 positive acute lymphoblastic leukemia (ALL). Blood, 122(21), 2013 2664–2664.
32. [32] Clinicaltrials.gov, Augmented Berlin-Frankfurt-Munster Therapy and Ofatumumab in Treating Patients with B-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma. Available at: www.clinicaltrials.gov (NCT02419469) 2010.
33. [33] Dalle, S., et al. Preclinical studies on the mechanism of action and the anti-lymphoma activity of the novel anti-CD20 antibody GA101. Mol. Cancer Ther. 10:1 (2011), 178–185.
34. [34] Awasthi, A., et al. Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody-dependent cytotoxicity and improves overall survival against CD20(+) rituximab-sensitive/-resistant Burkitt lymphoma (BL) and precursor B-acute lymphoblastic leukaemia (pre-B-ALL): potential targeted therapy in patients with poor risk CD20(+) BL and pre-B-ALL. Br. J. Haematol. 171:5 (2015), 763–775.
35. [35] Hu, Y., et al. Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model. Immunology 128:2 (2009), 260–270.
36. [36] Stock, W., Sanford, B., Lozanski, G., et al. Alemtuzumab can be incorporated into front-Line therapy of adult acute lymphoblastic leukemia (ALL): final phase I results of a cancer and leukemia group B study (CALGB 10102) [abstract]. Am. Soc. Hematol., 2009 Abstract 838.
37. [37] Angiolillo, A.L., et al. A phase II study of Campath-1H in children with relapsed or refractory acute lymphoblastic leukemia: a Children's Oncology Group report. Pediatr. Blood Cancer 53:6 (2009), 978–983.
38. [38] Lopus, M., et al. Maytansine and cellular metabolites of antibody-maytansinoid conjugates strongly suppress microtubule dynamics by binding to microtubules. Mol. Cancer Ther. 9:10 (2010), 2689–2699.
39. [39] Blanc, V., et al. SAR3419: an anti-CD19-maytansinoid immunoconjugate for the treatment of B-cell malignancies. Clin. Cancer Res. 17:20 (2011), 6448–6458.
40. [40] Carol, H., et al. The anti-CD19 antibody-drug conjugate SAR3419 prevents hematolymphoid relapse postinduction therapy in preclinical models of pediatric acute lymphoblastic leukemia. Clin. Cancer Res. 19:7 (2013), 1795–1805.
41. [41] Younes, A., et al. Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma. J. Clin. Oncol. 30:22 (2012), 2776–2782.
42. [42] Ribrag, V., et al. A dose-escalation study of SAR3419: an anti-CD19 antibody maytansinoid conjugate, administered by intravenous infusion once weekly in patients with relapsed/refractory B-cell non-Hodgkin lymphoma. Clin. Cancer Res. 20:1 (2014), 213–220.
43. [43] Kantarjian, H.M., et al. A phase II study of coltuximab ravtansine (SAR3419) monotherapy in patients with relapsed or refractory acute lymphoblastic leukemia. Clin. Lymphoma Myeloma Leuk. 16:3 (2016), 139–145.
44. [44] Fathi, A.T., Chen, R., Trippet, C.R., Interim analysis of a phase 1 study of the antibody-drug conjugate SGN-CD19A in relapsed or refractory B-Lineage acute leukemia and highly aggressive lymphoma [abstract]. Blood, 124(21), 2014 Abstract 963.
45. [45] Clinicaltrials.gov, A Safety Study of SGN-CD19A for Leukemia and Lymphoma. Available at: www.clinicaltrials.gov (NCT01786096).
46. [46] Nagorsen, D., et al. Blinatumomab: a historical perspective. Pharmacol. Ther. 136:3 (2012), 334–342.
47. [47] Topp, M.S., et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J. Clin. Oncol. 29:18 (2011), 2493–2498.
48. [48] Topp, M.S., et al. Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood 120:26 (2012), 5185–5187.
49. [49] Gökbuget, N., Dombret, H., Massimiliano, B., et al. Long-term outcomes after blinatumomab treatment: follow-up of a phase 2 study in patients with minimal residual disease positive B-cell precursor acute lymphoblastic leukemia [abstract]. Blood, 126(23), 2015.
50. [50] Topp, M.S., et al. Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J. Clin. Oncol. 32:36 (2014), 4134–4140.
51. [51] Topp, M.S., et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol. 16:1 (2015), 57–66.
52. ® blinatumomab in adult patients with relapsed/refractory B-precursor acute lymphoblastic leukemia (r/r ALL) post-allogeneic hematopoietic stem cell transplantation [abstract]. Blood, 126(23), 2015.
53. [53] Clinicaltrials.gov, Ph 3 Trial of Blinatumomab vs Investigator's Choice of Chemotherapy in Patients With Relapsed or Refractory ALL. Available at: www.clinicaltrials.gov (NCT02013167).
54. [54] Clinicaltrials.gov, Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia. Available at: www.clinicaltrials.gov (NCT02101853).
55. [55] Clinicaltrials.gov, A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults. Available at: www.clinicaltrials.gov (NCT02003222) 2013.
56. [56] Martinelli, G., Dombret, H., Chevallier, P., et al. Complete molecular and hematologic response in adult patients with relapsed/refractory (R/R) philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia (ALL) following treatment with blinatumomab: results from a phase 2 single-Arm, multicenter study (ALCANTARA) [abstract]. Blood, 126(23), 2015 Abstract 679.
57. [57] Shah, N.N., et al. Characterization of CD22 expression in acute lymphoblastic leukemia. Pediatr. Blood Cancer 62:6 (2015), 964–969.
58. [58] Raetz, E.A., et al. Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot Study. J. Clin. Oncol. 26:22 (2008), 3756–3762.
59. [59] Raetz, E.A., et al. Re-induction chemoimmunotherapy with epratuzumab in relapsed acute lymphoblastic leukemia (ALL): phase II results from Children's Oncology Group (COG) study ADVL04P2. Pediatr. Blood Cancer 62:7 (2015), 1171–1175.
60. [60] Clinicaltrials.gov, International Study for Treatment of Standard Risk Childhood Relapsed ALL 2010. Available at: www.clinicaltrials.gov (NCT01802814).
61. [61] Clinicaltrials.gov, Phase I/II Study Combining Humanised Anti-CD20 (Veltuzumab), Anti-CD22 (Epratuzumab) and Both Monoclonal Antibodies With Intensive Chemotherapy in Adults With Recurrent or Refractory B-precursor Acute Lymphoblastic Leukaemia (ALL). www.clinicaltrials.gov (NCT01279707).
62. [62] Clinicaltrials.gov, Phase II, Multicenter, Open Label, Prospective to Evaluate Efficacy and Tolerance of a Chemoimmunotherapy With HyperCVAD or Vincristine/Dexamethasone Plus the Anti-CD22 Monovlonal Antobody Epratuzumab for the Treatment of Adult Relapsed/Refractory CD22+ B-Acute Lymphoblastic Leukaemia Patients: CHEPRALL Study, a GRAALL Study. Available at: www.clinicaltrials.gov (NCT01219816).
63. [63] Chevallier, P., et al. (90)Y-labelled anti-CD22 epratuzumab tetraxetan in adults with refractory or relapsed CD22-positive B-cell acute lymphoblastic leukaemia: a phase 1 dose-escalation study. Lancet Haematol. 2:3 (2015), e108–17.
64. [64] Ricart, A.D., Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin. Clin. Cancer Res. 17:20 (2011), 6417–6427.
65. [65] Advani, A., et al. Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study. J. Clin. Oncol. 28:12 (2010), 2085–2093.
66. [66] Kantarjian, H., et al. Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. Lancet Oncol. 13:4 (2012), 403–411.
67. [67] Kantarjian, H., et al. Results of inotuzumab ozogamicin: a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia. Cancer 119:15 (2013), 2728–2736.
68. [68] DeAngelo, D.J., Stelljes, M., Martinelli, G., et al. Efficacy and safety of inotuzumab ozogamicin (INO) vs standard of care (SOC) in salvage 1 or 2 patients with acute lymphoblastic leukemia (ALL): an ongoing global phase 3 study [Abstract]. Eur. Hematol. Assoc., 2015 abstract LB2073.
69. [69] Jabbour, E., O'Brien, S., Nitin, O.b.S., et al. Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-hyper-CVD) as frontline therapy for older patients (≥ 60 years) with acute lymphoblastic leukemia (ALL). ASH Annual Meeting [abstract]. J. Clin. Oncol., 2014 Abstract 7019.
70. [70] Kreitman, R.J., et al. Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia. J. Clin. Oncol. 27:18 (2009), 2983–2990.
71. [71] Wayne, A.S., et al. Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial. Clin. Cancer Res. 16:6 (2010), 1894–1903.
72. [72] Wayne, A.S., Shah, N., Bhojwani, D., et al. Pediatric phase 1 trial of moxetumomab pasudotox: activity in chemotherapy refractory acute lymphoblastic leukemia (ALL) [abstract]. AACR Annual Meeting, 2014 Abstract CT230.